GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Asset Turnover

Estrella Immunopharma (Estrella Immunopharma) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Estrella Immunopharma's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Estrella Immunopharma's Total Assets for the quarter that ended in Mar. 2024 was $9.04 Mil. Therefore, Estrella Immunopharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Estrella Immunopharma's annualized ROE % for the quarter that ended in Mar. 2024 was -21.43%. It is also linked to ROA % through Du Pont Formula. Estrella Immunopharma's annualized ROA % for the quarter that ended in Mar. 2024 was -20.80%.


Estrella Immunopharma Asset Turnover Historical Data

The historical data trend for Estrella Immunopharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Asset Turnover Chart

Estrella Immunopharma Annual Data
Trend Jun21
Asset Turnover
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Estrella Immunopharma's Asset Turnover

For the Biotechnology subindustry, Estrella Immunopharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Asset Turnover falls into.



Estrella Immunopharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Estrella Immunopharma's Asset Turnover for the fiscal year that ended in Jun. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2021 )/( (Total Assets (A: . 20 )+Total Assets (A: Jun. 2021 ))/ count )
=/( (+)/ )
=/
=

Estrella Immunopharma's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (9.447+8.633)/ 2 )
=0/9.04
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Estrella Immunopharma  (NAS:ESLA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Estrella Immunopharma's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-1.88/8.772
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.88 / 0)*(0 / 9.04)*(9.04/ 8.772)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0306
=ROA %*Equity Multiplier
=-20.80 %*1.0306
=-21.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Estrella Immunopharma's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-1.88/9.04
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.88 / 0)*(0 / 9.04)
=Net Margin %*Asset Turnover
= %*0
=-20.80 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Estrella Immunopharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines